

The 4th International Electronic Conference on Antibiotics

21-23 May 2025 | Online

Microbial importance in the synthesis of chiral drugs and drug intermediates for the benefit of mankind Gopal Patel

Lakshmi Narain College of Pharmacy, <u>Bhopal, Madhya Pradesh, India-462021</u>

INTRODUCTION & AIM


Chirality is a key feature in drug molecules, as enantiomers (mirror-image forms) often exhibit different biological activities.

✤In many cases, only one enantiomer is therapeutically active, while the other may be less active, inactive, or even harmful.

Therefore, the production of enantiomerically pure (single-isomer) drugs is essential.

Design-Expert® Software Factor Coding: Actual Enzyme Activity Enzyme Activity actor Coding: Actua Design Point 4.54545 Design points above predicted v 4.5 4.54545 2.67532 2.67532 X1 = A: Yeast Ex. X2 = C: K2HPO4 X1 = A: Yeast Ex. X2 = C: K2HPO4 Actual Factors B: Meat Ex. = 10.00 Actual Factors B: Meat Ex. = 10.00 Activity C: K2HPO4 D: Glutamic acid = 1.00 D: Glutarnic acid = 1.00 3.00 -Enzyme 2.00 13.00 C: K2HPO A: Yeast Ex. A: Yeast Ex.

RESULTS & DISCUSSION




	5	maantura autori	Conditions	Harsh
Beneficial properties over other catalysis	Efficiency	Fast Selective Productive Available Patentable Cost-effective		Reusable Immobilizable
	Excellent	Sustainable Safe		Robust Evolvable

14

Enzyme Biocatalysis

Λ		O	

Culture Conditions




A. Teast Ex.

Response surface and contour plot showing the effect of Yeast extract and K₂HPO₄ on transaminase activity

Optimized Conditions

Sr No	Factor	Value
1	Galactose	5 g/L
2	Yeast extract	15 g/L
3	Meat extract	15 g/L
4	K_2HPO_4	4 g/L
5	Glutamic acid	1 g/L
6	Inoculum volume	2% (v/v)
7	Agitation rate	200 rpm
8	Initial pH	6
9	Temperature	37°C

Kinetic resolution of (*R*,*S*)-mexiletine by transaminase



Optimization of significant variables using Response Surface Methodology (RSM)

Concentration ranges of the factors used in Central Composite Design

Factors	Actual levels of coded factors			
	(-1)	0	(+1)	
Yeast Extract (g/L)	5	10	15	
Meat Extract (g/L)	5	10	15	
K ₂ HPO ₄ (g/L)	1	3	5	
Glutamic acid (g/L)	0.5	1	1.5	

CONCLUSION

As the demand for chiral drugs continues to grow, our role in the pharmaceutical industry will become increasingly important. Advances in genetic engineering, synthetic biology, and biocatalysis will enable us to develop new, efficient, and sustainable synthesis routes for complex molecules. The Microbial Network in Drug Synthesis is poised to play a vital role in shaping the future of chiral drug synthesis and contributing to the development of novel, life-changing therapeutics

FUTURE WORK / REFERENCES

- Production of transaminase can be further improved by incorporating strategies like medium and bioreactor engineering
- Effect of agitation and aeration need to be studied in a bioreactor.
- The enzyme may be purified and remaining work related to the biocatalysis may be done on (*R*,*S*)-mexiletine.

https://sciforum.net/event/ECA2025